Opdivo/Cabometyx combo hits targets in first-line kidney cancer
The combination significantly increased progression free survival when used as a first-line treatment
Read More
Tag: cabozantinib
Ipsen’s Cabometyx wins EU nod for liver cancer
Ipsen’s Cabometyx can now be used as monotherapy to treat certain patients with liver cancer following a green light from regulators in Europe.
Read More
NICE rejects Genzyme’s Caprelsa for medullary thyroid cancer
NICE has published draft guidelines rejecting Sanofi Genzyme’s Caprelsa for treating medullary thyroid cancer (MTC) that cannot be operated on or has spread around the body.
Read More
Four new therapies to be funded by NHS Scotland
The Scottish Medicines Consortium has endorsed NHS funding for four therapies, offering new treatment options for acute myeloid leukaemia, Still’s disease, adrenal insufficiency and psoriatic arthritis.
Read More
NICE u-turn recommends Ipsen’s Cabometyx for kidney cancer
NHS funding for Ipsen’s Cabometyx is now being recommended by the National Institute for Health and Care Excellence to treat kidney cancer.
Read More
NICE rules against first-line use of Ipsen’s Cabometyx
The National Institute for Health and Care Excellence has issued a preliminary decision rejecting first-line use of Ipsen/Exelixis’ Cabometyx in renal cancer on the NHS.
Read More
EU OKs first-line use of Ipsen’s Cabometyx
The European Commission has approved Ipsen/Exelixis’ Cabometyx for the first-line treatment of adults with advanced renal cell carcinoma (RCC).
Read More
Final NICE green light for Ipsen’s Cometriq
Ipsen’s Cometriq can now be routinely funded by the NHS to treat patients with medullary thyroid cancer (MTC) in England and Wales.
Read More
Cabometyx trial halted early on success in liver cancer
A late-stage trial assessing Ipsen and Exelixis’ Cabometyx in advanced liver cancer has been halted early after a significant improvement in overall survival was observed.
Read More
NICE rejects thyroid cancer drugs
It is looking likely that patients in England will loose NHS access to Ipsen’s Cometriq and Sanofi Genzyme’s Caprelsa via the Cancer Drugs Fund, after cost-regulators turned down funding for their use.
Read More
Price cut secures a place for Ipsen’s Cabomeytx on the NHS
Ipsen has cut the price of its kidney cancer Cabometyx to secure its place within the NHS’ routine commissioning stream, helping to over-turn a previous decision that it did not represent value for money.
Read More
Four new medicines win nod for NHS Scotland
The Scottish Medicines Consortium has accepted four new medicines for routine use by NHS Scotland, offering patients new options for kidney cancer, liver disease and the prevention of nausea and vomiting.
Read More
- Liverpool and McMaster University announce £300,000 strategic research partnership
- Study finds link between malaria parasites developing antimalarial drug resistance
- Researchers develop ‘digital twin’ heart models to better monitor PAH NHS patients
- Closed Loop and Pharmanovia investigate precision medicine combination in hypertension
- US study reveals interferon combinations cause lupus symptoms and affect treatment
